LY2886721 is an ß-site amyloid protein cleaving enzyme (BACE) inhibitor with the potential to inhibit the synthesis of ß-amyloid. LY2886721 inhibits recombinant hBACE1 with an IC50 of 20 nM. In cellular assays, LY2886721 inhibits Abeta with an IC50 range of 10-19 nM. LY2886721 can also targetγ-secretase to nhibit the synthesis of β-amyloid. Oral administration of LY2886721 to PDAPP mice produced dose-dependent reductions in brain Abeta, C99 and sAPPbeta. LY2886721 is currently in a Phase II clinical trial in patients with Mild Cognitive Impairment.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Related BACE Products|
The novel once-daily long-acting β2-agonist (LABA) olodaterol is a highly selective and nearly full β2 agonist that provides 24-h bronchodilation in patients with COPD.
AZD3293, also known as LY3314814 is an oral beta-secretase 1 cleaving enzyme (BACE) inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.